Financial Survey: MacroGenics (MGNX) & Jounce Therapeutics (JNCE)

MacroGenics (NASDAQ: MGNX) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.


This table compares MacroGenics and Jounce Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MacroGenics -1,526.55% -69.31% -58.09%
Jounce Therapeutics -2.03% -1.39% -0.50%

Analyst Ratings

This is a breakdown of recent ratings and target prices for MacroGenics and Jounce Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics 0 2 9 0 2.82
Jounce Therapeutics 0 0 4 0 3.00

MacroGenics currently has a consensus target price of $31.89, indicating a potential upside of 42.62%. Jounce Therapeutics has a consensus target price of $29.00, indicating a potential upside of 20.53%. Given MacroGenics’ higher possible upside, analysts plainly believe MacroGenics is more favorable than Jounce Therapeutics.

Valuation & Earnings

This table compares MacroGenics and Jounce Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MacroGenics $91.88 million 8.96 -$58.52 million ($4.50) -4.97
Jounce Therapeutics $37.20 million 20.86 -$13.70 million ($0.21) -114.57

Jounce Therapeutics has lower revenue, but higher earnings than MacroGenics. Jounce Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.5% of MacroGenics shares are held by institutional investors. Comparatively, 47.5% of Jounce Therapeutics shares are held by institutional investors. 8.3% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Jounce Therapeutics beats MacroGenics on 7 of the 12 factors compared between the two stocks.

MacroGenics Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company’s product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with's FREE daily email newsletter.

Leave a Reply